NASDAQ$BVS
Bioventus Inc - A · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Reported better-than-expected first quarter revenue results, driven primarily by accelerating U.S. sales growth trends and completed acquisition of Bioness.
Bioventus Inc. reported a 4.0% increase in net sales, a 133.9% increase in net income, and completed the acquisition of Bioness. They also raised full year 2021 revenue guidance by $4 million.
- Net Sales of $81.8 million, up 4.0% year-over-year.
- Net Income of $24.5 million, up 133.9% year-over-year.
- Adjusted EBITDA of $11.1 million, down 22.3% year-over-year.
- Completed acquisition of Bioness on March 30, 2021.
Headline financials
Revenue & EPS history
Bioventus · Revenue · Quarterly
$81.8M
Forward guidance
The Company now expects net sales of $394 million to $406 million, up approximately 23% to 26% year-over-year.
Tailwinds
- Net sales from legacy Bioventus Inc. of $364 million to $374 million, representing Organic Revenue Growth in the range of approximately 13% to 16% year-over-year.
- Net sales from the acquisition of Bioness Inc., following the closing date of March 30, 2021, of approximately $30 million to $32 million.
- Net income from legacy Bioventus, Inc. of $33.8 million to $38.2 million
- Non-GAAP net income from legacy Bioventus Inc. of $69.0 million to $71.7 million
- Adjusted EBITDA from legacy Bioventus, Inc. of $81.2 million to $85.4 million
Headwinds
- Net income of $12.0 million to $19.2 million, compared to net income of $14.7 million for the twelve months ended December 31, 2020.
- Net loss from the acquisition of Bioness, Inc., following the closing date of March 30, 2021, of approximately ($21.8) million to ($19.0) million.
- Non-GAAP net loss from the acquisition of Bioness, Inc., following the closing date of March 30, 2021, of approximately ($9.3) million to ($6.5) million.
- Adjusted EBITDA loss from the acquisition of Bioness, Inc., following the closing date of March 30, 2021, of approximately ($7.3) million to ($4.5) million.
- Net sales of $394 million to $406 million
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+2.1%
Avg return
Earnings day
+5.6%
Avg return
5 days after
+13.1%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+26.0%
Q1 2024
Best reaction
-39.9%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.2% | -4.6% | -15.4% | |
| Q4 2025 | +7.4% | +4.6% | +5.9% | |
| Q3 2025 | +15.1% | +13.6% | +16.2% | |
| Q1 2025 | -12.0% | -5.0% | -7.4% | |
| Q4 2024 | +23.3% | +9.7% | -13.6% | |
| Q3 2024 | -17.7% | -13.8% | -15.1% | |
| Q2 2024 | +19.2% | +21.2% | +54.3% | |
| Q1 2024 | +26.0% | +35.0% | +70.0% | |
| Q4 2023 | -0.4% | +2.6% | -9.4% | |
| Q3 2023 | +6.0% | -2.1% | +42.1% | |
| Q2 2023 | +20.3% | +32.9% | -2.6% | |
| Q1 2023 | +6.5% | +58.5% | +195.9% | |
| Q4 2022 | -6.6% | +2.5% | -16.5% | |
| Q3 2022 | -39.9% | -42.7% | -18.9% | |
| Q2 2022 | +4.8% | +3.9% | -6.4% | |
| Q1 2022 | -9.1% | +4.5% | +12.5% | |
| Q4 2021 | +0.8% | -3.0% | -4.0% | |
| Q3 2021 | -0.5% | -4.5% | -18.7% | |
| Q2 2021 | +1.7% | +0.3% | -0.7% | |
| Q1 2021 | +1.0% | +3.3% | +17.0% | |
| Q4 2020 | -4.8% | -0.4% | -9.1% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q1 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro